The global wearable injectors market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 15% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use sectors. These insights are included in the report as a major market contributor.
Wearable injectors, or patch pumps, are compact drug delivery devices used for single-step administration of medicines for longer durations. They are temporarily pasted on the skin to deliver viscous drugs in large volumes faster and safely through the subcutaneous tissues in the body. They are commonly available in on-body and off-body injector variants and the device consists of a reservoir to store medicine, a cannula for substance delivery to tissues and a drive system to deliver the appropriate drug volume. In comparison to the traditionally used vials and syringes, wearable injectors are disposable, user-friendly, cause minimal discomfort and pain. As a result, they are widely used in the treatment of cancer, diabetes, rheumatoid arthritis and cardiovascular diseases.
The increasing prevalence of chronic medical ailments, such as oncological, neurological and autoimmune disorders, is of the key factors driving the market growth. Moreover, the rising geriatric population, which is more susceptible to such ailments, and the increasing demand for minimally invasive (MI) treatment alternatives among the patients are providing a thrust to the growth of the market. There is also a growing preference for at-home and self-administrable injectors to effectively manage the ailments with minimal risks of inaccurate dosage and needle stick injuries. Additionally, various product innovations, such as integration of passive warning systems, wireless connectivity and Bluetooth technologies with the injectors, are acting as other growth-inducing factors. These technologies facilitate convenient monitoring of the patient through a smartphone application and provide timely reminders for dosages. Other factors, including extensive research and development activities, along with significant improvements in the healthcare infrastructure, especially in the developing economies, are anticipating to the drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global wearable injectors market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, type, technology, application and end use.
Breakup by Type:
Breakup by Technology:
Breakup by Application:
Breakup by End Use:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Becton Dickinson and Company, CeQur SA, Debiotech SA, Dexcom Inc., Enable Injections Inc., Gerresheimer AG, Insulet Corporation, Tandem Diabetes Care Inc., West Pharmaceutical Services Inc. and Ypsomed AG.
|Base Year of the Analysis||2020|
|Segment Coverage||Type, Technology, Application, End Use, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Becton Dickinson and Company, CeQur SA, Debiotech SA, Dexcom Inc., Enable Injections Inc., Gerresheimer AG, Insulet Corporation, Tandem Diabetes Care Inc., West Pharmaceutical Services Inc. and Ypsomed AG.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at